Kisspeptin & HPG-Axis Drugs as a Future Class
Kisspeptin, Neurokinin-B Modulators, and Targeting the Top of the Reproductive Axis
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Investigational; no approved kisspeptin product for sexual function
Reference only. Not medical advice.
What can go wrong
In trials, kisspeptin has been well-tolerated at the doses used, a notable feature versus more side-effect-laden agents. But long-term safety, repeated dosing, and a practical delivery format are unestablished, and the studies are small. Gray-market kisspeptin sold through peptide vendors for libido is unregulated, of unverified purity, and not supported by any approval; it should not be conflated with the controlled research.
This is something to take to a clinician. The Atlas can tell you what is known about kisspeptin & hpg-axis drugs as a future class in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Kisspeptin is a hypothalamic neuropeptide at the very top of the hypothalamic-pituitary-gonadal (HPG) axis: it drives GnRH release, and thus LH, FSH, and testosterone. Waljit Dhillo's group at Imperial College London has run the most notable human work, including placebo-controlled studies (e.g., Comninos et al.) showing kisspeptin administration enhances brain responses to sexual/emotional stimuli and, in a 2023 JAMA Network Open trial, improved sexual responses in men with low desire, distinct from simply raising testosterone. The broader class includes neurokinin-B and related neuromodulators of the KNDy neuron system (the same biology behind the menopause drug fezolinetant). It is genuinely promising and genuinely early: no approved product for sexual function, and trials remain small. The appeal is acting on the upstream regulator of both hormone output and central arousal.
A brain peptide that sits above testosterone itself, and seems to boost both desire and arousal in trials.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Kisspeptin neurons (in the arcuate and AVPV hypothalamic nuclei) are the master gatekeepers of reproduction: they stimulate GnRH neurons, triggering pituitary LH/FSH release and downstream gonadal testosterone production. Beyond hormone control, kisspeptin signaling appears to act within limbic/sexual-processing brain regions, modulating arousal and emotional responses to sexual stimuli directly. So kisspeptin can, in principle, influence sexual function through two routes, raising the hormonal substrate AND enhancing central arousal circuitry, which is what the Imperial fMRI and clinical studies probed. Neurokinin-B and dynorphin co-regulate these KNDy neurons, defining a druggable network.
The catch: striking mechanism, small trials, no product
The human data are mechanistically elegant but early-stage: sample sizes are small (dozens), administration in studies is typically infusion/injection (not a convenient consumer format), durability is unestablished, and there is no approved kisspeptin therapeutic for sexual function. The neurokinin/KNDy biology has yielded one approved drug in a different indication (fezolinetant for menopausal hot flushes via NK3 antagonism), which validates the network as druggable, but does not establish a sexual-health product. This is a promising future class, not a present therapy, and any commercial 'kisspeptin' sold for libido today is gray-market and unproven.
What people get wrong
Often saidKisspeptin is just a testosterone booster
ActuallyIt sits above testosterone in the axis AND appears to act on central arousal circuits directly; trials suggest effects beyond raising testosterone.
Often saidYou can buy proven kisspeptin therapy
ActuallyThere is no approved kisspeptin product for sexual function. Trials are small and ongoing; gray-market peptide versions are unverified.
Who profits, and who pushes back
Waljit Dhillo, MBBS PhD
Kisspeptin shows real promise for low sexual desire by acting on the brain's arousal pathways, but the studies are early and a usable therapy is some way off.
What we do not know
- Can a convenient, durable kisspeptin formulation be developed?
- How large is the effect in well-powered trials, and in which patients?
- Does combining HPG-axis and central-arousal targeting outperform single mechanisms?
At a glance
- Position
- Top of the HPG axis (drives GnRH)
- Lead group
- Waljit Dhillo, Imperial College London
- Notable trial
- Comninos et al., JAMA Netw Open 2023 (men, low desire)
- Approved sexual-function product
- None
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Kisspeptin & HPG-Axis Drugs as a Future Class. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Comninos et al. (JCI / J Clin Invest)2017
Kisspeptin administration enhanced brain activity in sexual/emotional-processing regions in men (fMRI)
Comninos/Dhillo et al. (JAMA Network Open)2023
Placebo-controlled trial: kisspeptin improved sexual responses in men with low sexual desire, beyond testosterone effects
Fezolinetant (NK3 antagonist) approval2023
Validated the neurokinin-B/KNDy network as druggable (menopause indication), supporting the broader class